Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.